Key facts
- Satsuma Pharmaceuticals will present clinical development program findings.
- The presentation is at the American Headache Society's 68th Annual Scientific Meeting.
- The focus is on innovative treatments for people living with migraine.
Satsuma Pharmaceuticals, Inc., a biopharmaceutical company dedicated to developing innovative treatments for migraine sufferers, has announced that two abstracts detailing findings from its clinical development program will be presented at the American Headache Society's 68th Annual Scientific Meeting. This presentation underscores Satsuma's commitment to advancing therapeutic options for individuals impacted by migraine.